EGFR and non-small cell lung carcinoma: Regarding whether this chemo-free antiangiogenic agent plus ICIs regimen could become the preferred later-line option for patients in whom EGFR-TKIs fail, our study provides important contributions to the evidence on the efficacy and safety of this combination regimen in previously treated patients with EGFR-mutant advanced NSCLC.